Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | SYNIMMUNE GmbH: |
Description | SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy |
Keywords | SYNIMMUNE, bispecific, antibody, monoclonal, therapeutic, immunotherapy, hematopoietic |
WebSite | synimmune.de |
Host IP | 185.15.195.231 |
Location | Germany |
Site | Rank |
US$753,595
Last updated: 2022-07-01 23:58:26
synimmune.de has Semrush global rank of 14,045,085. synimmune.de has an estimated worth of US$ 753,595, based on its estimated Ads revenue. synimmune.de receives approximately 86,954 unique visitors each day. Its web server is located in Germany, with IP address 185.15.195.231. According to SiteAdvisor, synimmune.de is safe to visit. |
Purchase/Sale Value | US$753,595 |
Daily Ads Revenue | US$696 |
Monthly Ads Revenue | US$20,869 |
Yearly Ads Revenue | US$250,426 |
Daily Unique Visitors | 5,797 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
synimmune.de. | A | 86398 | IP: 185.15.195.231 |
synimmune.de. | NS | 86400 | NS Record: b.ns14.net. |
synimmune.de. | NS | 86400 | NS Record: d.ns14.net. |
synimmune.de. | NS | 86400 | NS Record: c.ns14.net. |
synimmune.de. | NS | 86400 | NS Record: a.ns14.net. |
synimmune.de. | MX | 86400 | MX Record: 50 mx4.agenturserver.de. |
synimmune.de. | MX | 86400 | MX Record: 10 mx2.agenturserver.de. |
synimmune.de. | MX | 86400 | MX Record: 10 mx1.agenturserver.de. |
synimmune.de. | MX | 86400 | MX Record: 20 mx3.agenturserver.de. |
Skip to navigation Skip to content Welcome NEWS Company Management Board Advisory Board Investors Technology Fc-optimized antibodies Bispecific antibodies SYNIMMUNE’s Bispecific Antibody Platform Products Product Pipeline FLYSYN TACSYN Partnering Home » Welcome Welcome to SYNIMMUNE SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity. For AML Patients |
HTTP/1.1 301 Moved Permanently Date: Wed, 27 Oct 2021 16:51:27 GMT Server: Apache Set-Cookie: fe_typo_user=04916b7bc95c83e3843687cbfd400adc; path=/ Upgrade: h2,h2c Connection: Upgrade Location: https://www.synimmune.de/ Content-Type: text/html HTTP/2 301 date: Wed, 27 Oct 2021 16:51:27 GMT server: Apache set-cookie: fe_typo_user=df90f62908c8c05a8d06a84d8adb9a21; path=/ location: https://www.synimmune.de/welcome/ content-type: text/html HTTP/2 200 date: Wed, 27 Oct 2021 16:51:28 GMT server: Apache expires: Wed, 27 Oct 2021 23:45:26 GMT cache-control: max-age=24838 pragma: public set-cookie: fe_typo_user=b011f3f0d04dea27730c7c95297c27b0; path=/ last-modified: Wed, 15 Sep 2021 10:55:57 GMT etag: "1b7cc448c7bc80be110ddf5ad2c6fed4" content-type: text/html; charset=utf-8 |